Abbott Laboratories stock rises 1.14% and outperforms market in weak session

13 articles · Updated · MarketWatch · Apr 28

Abbott shares closed at $93.86 on Tuesday, marking a second consecutive day of gains despite the S&P 500 and Dow Jones both declining.
The stock outperformed competitors Johnson & Johnson, Pfizer, and Merck, with trading volume matching its 50-day average of 11.5 million shares.
Abbott remains 32.50% below its 52-week high of $139.06, reached on June 24, highlighting ongoing recovery challenges amid broader market weakness.

Why is Wall Street bullish on Abbott despite major lawsuits and product recalls?

With its Nutrition segment struggling, can medical devices alone carry Abbott's growth?

Is Abbott's $21 billion bet on cancer diagnostics a smart move or a risky distraction?

Can Abbott's new cancer unit offset its massive infant formula legal costs?

After a fatal recall, how can patients trust Abbott's popular glucose monitors?

Does Abbott's recall signal a wider safety problem for AI in medical devices?